semaglutide Use of linked to doubled risk of neovascular macular degeneration Semaglutide IM - Natural Endocrinology
Description
By week 68, participants who took semaglutide lost an average of 15.1% of their body weight, compared to 2.4% in the placebo group
This table from a 2025 meta-analysis shows the average weight change compared to a control group after stopping anti-obesity medications
Focus on quality over quantity
Urocortin reduces food intake and gastric emptying in lean and ob/ob obese mice
